There is little information about body weight and body composition (BC) among users of the levonorgestrel-releasing intrauterine system (LNG-IUS). The aim of this study was to evaluate body weight and BC in LNG-IUS users compared to users of the TCu380A intrauterine device (IUD).
Study Design
A prospective study was done with 76 new users of both contraceptive methods. Women were paired by age (±2 years) and body mass index (BMI, kg/m², ±2). Body weight and BC (% lean mass and % fat mass) were evaluated by a trained professional at baseline and at 1 year of contraceptive use. The BC measurements were obtained using Lunar DXA equipment. Weight and BC were evaluated in each woman at baseline and at 12 months and analyzed as the mean change within each woman. Then, the changes in weight and BC for each woman were calculated and then compared between LNG-IUS and TCu380A IUD users (paired data for each woman). The central-to-peripheral fat ratio was calculated by dividing trunk fat by the upper and lower limb fat.
Results
There were no significant differences at time of IUD insertion between LNG-IUS and TCu380A IUD users regarding age (mean±SD) (34.4±7.5 vs. 33.9±8.0 years), BMI (25.3±4.1 vs. 25.9±4.1) and number of pregnancies (1.9±0.2 vs. 1.7±0.2), respectively. Mean body weight gain of 2.9 kg was observed among LNG-IUS users at 12 months (p=.0012), whereas the body weight of TCu380A IUD users only increased by 1.4 kg (p=.067). There was no significant difference in body weight change between the two groups of users at 12 months. The variation in the central-to-peripheral fat ratio was the same between the two groups (-1.6% vs. -0.2%; p=.364). LNG-IUS users showed a 2.5% gain in fat mass (p=.0009) and a 1.4% loss of lean mass, whereas TCu380A IUD users showed a loss of 1.3% of fat mass (p=.159) and gain of 1.0% of lean mass (p=.120). TCu380A IUD users gained more lean mass than LNG-IUS users (p=.0270), although there was no significant difference between the two groups after 12 months of use.
Conclusions
Although an increase in mean fat mass among LNG-IUS users at 12 months of use was observed, it should be noted that an increase of body weight was also observed in both groups after 1 year of insertion of the device. However, a study with a larger number of women and long-term evaluation is necessary to evaluate these body changes.
levonorgestrel intrauterine system body weight composition, LNG-IUS body weight gain fat mass DXA, hormonal IUD weight gain versus copper IUD, LNG-IUS TCu380A body composition prospective comparison, levonorgestrel IUS lean mass fat mass changes, intrauterine device body composition DXA measurement, Mirena weight gain fat mass one year, copper IUD versus hormonal IUD body weight, central peripheral fat ratio LNG-IUS users, Bahamondes LNG-IUS body weight prospective study
PMID 22445431 22445431 DOI 10.1016/j.contraception.2012.01.017 10.1016/j.contraception.2012.01.017
Cite this article
Dal'Ava, N., Bahamondes, L., Bahamondes, M. V., de Oliveira Santos, A., & Monteiro, I. (2012). Body weight and composition in users of levonorgestrel-releasing intrauterine system. *Contraception*, *86*(4), 350-353. https://doi.org/10.1016/j.contraception.2012.01.017
Dal'Ava N, Bahamondes L, Bahamondes MV, de Oliveira Santos A, Monteiro I. Body weight and composition in users of levonorgestrel-releasing intrauterine system. Contraception. 2012;86(4):350-353. doi:10.1016/j.contraception.2012.01.017
Dal'Ava, N., et al. "Body weight and composition in users of levonorgestrel-releasing intrauterine system." *Contraception*, vol. 86, no. 4, 2012, pp. 350-353.
Toffol E et al., 2011Human Reproduction (Oxford, England)
Background: The effects of oral contraceptives (OCs) on mental health are not clear, and no study has been focused on the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) on menta...
Contraception/Comparison > Side Effects > Mental Health EffectsContraception/Comparison > Hormonal Contraception > Oral ContraceptivesContraception/Comparison > Hormonal Contraception > Levonorgestrel IUS
Objective: To examine trends in national reporting of broken intrauterine devices (IUDs).
Study Design: We enumerated IUD device "breakage" reports in the Food and Drug Administration Adverse Event R...
Objective: To evaluate overall and subgroup efficacy of an estetrol (E4) 15 mg drospirenone (DRSP) 3 mg oral contraceptive in a 24/4-day regimen.
Study Design: We pooled efficacy outcomes from 2 pivo...
Objective: The Natural Cycles app employs daily basal body temperature to define the fertile window via a proprietary algorithm and is clinically established effective in preventing pregnancy. We soug...